Literature DB >> 9571159

Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.

A Tomoyasu1, M Goto, N Fujise, S Mochizuki, H Yasuda, T Morinaga, E Tsuda, K Higashio.   

Abstract

Osteoclastogenesis inhibitory factor (OCIF) is present naturally as two molecular forms, a monomer and a homodimer. The two forms of recombinant human OCIF (rOCIF) produced by Chinese hamster ovary (CHO) cells were purified to homogeneity. Determination of the C-terminal amino-acid sequences of the two forms of rOCIF revealed that the monomeric rOCIF lacked several amino acids including Cys379, which is involved in the intermolecular disulfide bond, in its C-terminal region. The two forms of rOCIF were indistinguishable in stability, sialic acid content, and specific activity in inhibition of osteoclastogenesis. In contrast, the homodimeric rOCIF was stronger in heparin-binding ability than the monomeric rOCIF. The homodimeric rOCIF was significantly shorter in initial half-life and smaller in AUC value in rats than the monomeric rOCIF, but exerted more potent biological activity in reducing the calcium concentration in serum of rats than did the monomeric rOCIF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9571159     DOI: 10.1006/bbrc.1998.8443

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats.

Authors:  Yoshihiro Miyaji; Yuji Kasuya; Yoshitake Furuta; Atsushi Kurihara; Masayuki Takahashi; Ken-Ichi Ogawara; Takashi Izumi; Osamu Okazaki; Kazutaka Higaki
Journal:  Pharm Res       Date:  2012-06-23       Impact factor: 4.200

Review 2.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

3.  Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.

Authors:  T Miyashita; A Kawakami; T Nakashima; S Yamasaki; M Tamai; F Tanaka; M Kamachi; H Ida; K Migita; T Origuchi; K Nakao; K Eguchi
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

4.  Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.

Authors:  A Dovio; D Generali; M Tampellini; A Berruti; S Tedoldi; M Torta; S Bonardi; M Tucci; G Allevi; S Aguggini; A Bottini; L Dogliotti; A Angeli
Journal:  Osteoporos Int       Date:  2007-08-17       Impact factor: 4.507

5.  Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy.

Authors:  A Jorsal; L Tarnow; A Flyvbjerg; H-H Parving; P Rossing; L M Rasmussen
Journal:  Diabetologia       Date:  2008-08-22       Impact factor: 10.122

6.  Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells.

Authors:  E Y Liao; X H Luo; X Su
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

Review 7.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

Review 8.  The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.

Authors:  Daniela-Eugenia Malliga; Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2011-09-02

9.  Murine osteoclasts secrete serine protease HtrA1 capable of degrading osteoprotegerin in the bone microenvironment.

Authors:  Nagahiro Ochiai; Yutaka Nakachi; Tomotaka Yokoo; Takahiro Ichihara; Tore Eriksson; Yuki Yonemoto; Takehiko Kato; Hitoshi Ogata; Natsuko Fujimoto; Yasuhiro Kobayashi; Nobuyuki Udagawa; Shinsuke Kaku; Tomokazu Ueki; Yasushi Okazaki; Naoyuki Takahashi; Tatsuo Suda
Journal:  Commun Biol       Date:  2019-03-01

10.  Nitidine chloride prevents OVX-induced bone loss via suppressing NFATc1-mediated osteoclast differentiation.

Authors:  Qian Liu; Tao Wang; Lin Zhou; Fangming Song; An Qin; Hao Tian Feng; Xi Xi Lin; Zhen Lin; Jin Bo Yuan; Jennifer Tickner; Hua Gang Liu; Ming Hao Zheng; Jiake Xu; Jin Min Zhao
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.